NCT05194124Phase 3Completed

Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

Study sponsor: Rhythm Pharmaceuticals, Inc. · RYTM

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-10-19Actual
Enrollment · participants19Actual
Source updated2024-11-26Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview